In the last trading session, 1.63 million shares of the BridgeBio Pharma Inc (NASDAQ:BBIO) were traded, and its beta was 1.08. Most recently the company’s share price was $31.12, and it changed around -$0.64 or -2.02% from the last close, which brings the market valuation of the company to $5.88B. BBIO currently trades at a discount to its 52-week high of $41.04, offering almost -31.88% off that amount. The share price’s 52-week low was $21.62, which indicates that the current value has risen by an impressive 30.53% since then. We note from BridgeBio Pharma Inc’s average daily trading volume that its 10-day average is 2.67 million shares, with the 3-month average coming to 2.53 million.
BridgeBio Pharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 3 recommended BBIO as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight. BridgeBio Pharma Inc is expected to report earnings per share of -1.09 for the current quarter.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Instantly BBIO has showed a red trend with a performance of -2.02% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 34.20 on recent trading dayincreased the stock’s daily price by 9.01%. The company’s shares are currently up 13.41% year-to-date, but still down -5.64% over the last five days. On the other hand, BridgeBio Pharma Inc (NASDAQ:BBIO) is 7.02% up in the 30-day period. We can see from the shorts that 18.78 million shares have been sold at a short interest cover period of 6.67 day(s).
The consensus price target as assigned by Wall Street analysts is $46, which translates to bulls needing to increase their stock price by 32.35% from its current value. Analyst projections state that BBIO is forecast to be at a low of $45 and a high of $53.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
The year-over-year growth rate is expected to be 2,928.71%, up from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 4.04M in revenue for the current quarter. 7 analysts expect BridgeBio Pharma Inc to make 46.48M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.75M and 211.12M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 131.48%. Forecasts for the next quarter put sales growth at -77.98%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.29%. BridgeBio Pharma Inc earnings are expected to increase by 36.36% in 2025, but the outlook is positive 15.02% per year for the next five years.
BBIO Dividends
BridgeBio Pharma Inc’s next quarterly earnings report is expected to be released in March.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.92% of BridgeBio Pharma Inc shares, and 92.81% of them are in the hands of institutional investors. The stock currently has a share float of 95.60%. BridgeBio Pharma Inc stock is held by 352.0 institutions, with KOHLBERG KRAVIS ROBERTS & CO. L.P. being the largest institutional investor. By 2024-06-30, it held 16.5582% of the shares, which is about 31.06 million shares worth $786.77 million.
VIKING GLOBAL INVESTORS LP, with 13.3917% or 25.12 million shares worth $636.31 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 4.53 shares worth $141.03 million, making up 2.40% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 3.93 shares worth around $122.36 million, which represents about 2.08% of the total shares outstanding.
